# EDGAR Filing Document

**Accession Number:** 0001385818
**File Stem:** 0001437749-25-019599
**Filing Date:** 2025-6
**Character Count:** 19049
**Document Hash:** 75e272eb24ec0b20af0ac4099648ac8d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-25-019599.hdr.sgml**: 20250606

**ACCESSION NUMBER**: 0001437749-25-019599

**CONFORMED SUBMISSION TYPE**: S-1MEF

**PUBLIC DOCUMENT COUNT**: 5

**FILED AS OF DATE**: 20250606

**DATE AS OF CHANGE**: 20250606

**EFFECTIVENESS DATE**: 20250606

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AYTU BIOPHARMA, INC
- **CENTRAL INDEX KEY:** 0001385818
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 470883144
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** S-1MEF
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-287825
- **FILM NUMBER:** 251028753

**BUSINESS ADDRESS:**
- **STREET 1:** 7900 E. UNION AVENUE
- **STREET 2:** SUITE 920
- **CITY:** DENVER
- **STATE:** CO
- **ZIP:** 80237
- **BUSINESS PHONE:** (720) 437-6580

**MAIL ADDRESS:**
- **STREET 1:** 7900 E. UNION AVENUE
- **STREET 2:** SUITE 920
- **CITY:** DENVER
- **STATE:** CO
- **ZIP:** 80237

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AYTU BIOSCIENCE, INC
- **DATE OF NAME CHANGE:** 20150609

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AYTU BIOSCIENCE, INC.
- **DATE OF NAME CHANGE:** 20150609

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Rosewind CORP
- **DATE OF NAME CHANGE:** 20070110

**As filed with the U.S. Securities and Exchange Commission on June 5, 2025**

**Registration No. 333-** 

**UNITED STATES**<br> **SECURITIES AND EXCHANGE COMMISSION**<br> **Washington, D.C. 20549**

**FORM S-1**<br> **REGISTRATION STATEMENT**<br> **UNDER THE**<br> **SECURITIES ACT OF 1933**

![logo01.jpg](logo01.jpg)

**AYTU BIOPHARMA, INC.**<br> (Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware**<br> (State or other jurisdiction of<br> incorporation or organization) | **2834**<br> (Primary Standard Industrial<br> Classification Code Number) | **47-0883144**<br> (I.R.S. Employer<br> Identification Number) |

---

**7900 East Union Avenue, Suite 920**<br> **Denver, Colorado 80237**<br> **(720) 437-6580**<br> (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

**Joshua R. Disbrow**<br> **Chief Executive Officer**

**Aytu BioPharma, Inc.**<br> **7900 East Union Avenue, Suite 920**<br> **Denver, Colorado 80237**<br> **Telephone: (720) 437-6580**<br> (Name, address, including zip code, and telephone number, including area code, of agent for service)

***Copies to:***<br>

---

| | |
|:---|:---|
| **Anthony W. Epps**<br> **Joshua B. Erekson**<br> **Dorsey & Whitney LLP**<br> **1400 Wewatta Street, Suite 400**<br> **Denver, Colorado 80202**<br> **(303) 352-1109** | **David Danovitch**<br> **Aaron Schleicher**<br> **Sullivan & Worcester LLP**<br> **1251 Avenue of the Americas**<br> **New York, New York 10019**<br> **(212) 660-3060** |

---

------

**Approximate date of commencement of proposed sale to the public**: As soon as practicable after the effective date of this registration statement.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box: ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ (333-287728)

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**This Registration Statement shall become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(b) under the Securities Act of 1933, as amended.**

------

**EXPLANATORY NOTE**

This 462(b) Registration Statement relates to the public offering of securities (the "Offering") contemplated by the Registration Statement on Form S-1, as amended, (File No. 333-287728) which was initially filed with the United States Securities and Exchange Commission (the "SEC") on June 2, 2025, and which was declared effective by the SEC on June 5, 2025 (the "Prior Registration Statement").

This Registration Statement on Form S-1 is being filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, for the purposes of registering additional securities of the same class as were included in the Prior Registration Statement, representing an increase in the maximum aggregate offering price by $2,760,000, which includes $2,400,000 worth of shares of the Company's common stock, par value $0.0001 per share ("Common Stock") and/or an additional $2,400,000 worth of prefunded warrants to purchase $2,400,000 worth of shares of Common Stock to be issued to the underwriters and an additional $360,000 worth of shares of Common Stock to be issued to the underwriters as an underwriters' option.

The additional securities that are being registered for sale are in an amount and at a price that together represents no more than 20% of the maximum aggregate offering price set forth in Exhibit 107 to the Prior Registration Statement.

The contents of the Prior Registration Statement and all exhibits thereto are hereby incorporated by reference.

The required opinion and consents are listed on an Exhibit Index attached hereto and filed herewith.

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit No.** | **Exhibit Description**  |
| 5.1 | [Opinion of Dorsey & Whitney LLP.](ex_827551.htm) |
| 23.1 | [Consent of Grant Thornton LLP, Independent Registered Public Accounting Firm.](ex_827687.htm) |
| 23.2 | [Consent of Dorsey & Whitney LLP (included in Exhibit 5.1).](ex_827551.htm) |
| 24.1\* | [Power of Attorney.](http://www.sec.gov/ix?doc=/Archives/edgar/data/0001385818/000143774925019189/aytu20250530_s1.htm#poa) |
| 107 | [Filing Fee Table.](ex_827712.htm) |
| \* | Previously filed on the signature page to the Prior Registration Statement and incorporated by reference herein. |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Denver, State of Colorado, on June 5, 2025.

---

| | |
|:---|:---|
| **AYTU BIOPHARMA, INC**.  | **AYTU BIOPHARMA, INC**.  |
| By: | /s/ Joshua R. Disbrow |
| Name: Joshua R. Disbrow | Name: Joshua R. Disbrow |
| Title: Chief Executive Officer | Title: Chief Executive Officer |

---

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated:

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Joshua R. Disbrow |  | June 5, 2025 |
| Joshua R. Disbrow | Chief Executive Officer and Director (*Principal Executive Officer*) |  |
| \* |  | June 5, 2025 |
| Ryan J. Selhorn | Chief Financial Officer (*Principal Financial and Accounting Officer*) |  |
| \* |  | June 5, 2025 |
| John A. Donofrio, Jr. | Chairman |  |
| \* |  | June 5, 2025 |
| Carl C. Dockery | Director |  |
| \* |  | June 5, 2025 |
| Abhinav Jain | Director |  |
| \* |  | June 5, 2025 |
| Vivian Liu | Director |  |

---

\* /s/ Joshua R. Disbrow Attorney-in-Fact

## Exhibit 5.1

**Exhibit 5.1**

June 5, 2025

Aytu BioPharma, Inc.

7900 East Union Avenue, Suite 920

Denver, Colorado 80237

Re: <u>Registration Statement on Form S-1 (File No. 333-287728)</u>

Ladies and Gentlemen:

We have acted as counsel to Aytu BioPharma Inc., a Delaware corporation (the "<u>Company</u>"), in connection with (i) a Registration Statement on Form S-1 (File No. 333-287728) (the "<u>Initial Registration Statement</u>") and (ii) a second Registration Statement on Form S-1 (the "<u>Rule 462(b) Registration Statement</u>" and, together, with the Initial Registration Statement, the "<u>Registration Statement</u>") and the related prospectus filed by the Company with the Securities and Exchange Commission (the "<u>Commission</u>") under the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), relating to the registration by the Company of (i) up to $2,400,000 worth of shares (the "<u>Offered Shares</u>") of the Company's common stock, par value $0.0001 per share (the "<u>Common Stock</u>") and/or (ii) pre-funded warrants (the "<u>Pre-Funded Warrants</u>") exercisable for up to $2,400,000 worth of shares of Common Stock (the "<u>Pre-Funded Warrant Shares</u>") to be sold pursuant to the Underwriting Agreement (the "<u>Underwriting Agreement</u>") to be entered into by and between the Company and Lake Street Capital Markets, LLC, as representative of the several underwriters listed therein (the "<u>Underwriters</u>"). In addition, the 462(b) Registration Statement registers an additional $360,000 worth of shares of the Company's Common Stock (the "<u>Optional Stock</u><u>"</u>). The Offered Shares, the Pre-Funded Warrants, the Pre-Funded Warrant Shares, and the Optional Stock, to be sold by the Company are collectively referred to as the "<u>Securities</u>."

We have examined such documents and have reviewed such questions of law as we have considered necessary or appropriate for the purposes of our opinions set forth below. In rendering our opinions set forth below, we have assumed the authenticity of all documents submitted to us as originals, the genuineness of all signatures and the conformity to authentic originals of all documents submitted to us as copies. We have also assumed the legal capacity for all purposes relevant hereto of all natural persons. As to questions of fact material to our opinions, we have relied upon certificates or comparable documents of officers and other representatives of the Company and of public officials.

Based on the foregoing, we are of the opinion that:

&nbsp;&nbsp;&nbsp;&nbsp;1. The Offered Shares and Optional Stock, when issued and delivered against payment of the consideration therefor specified in the Underwriting Agreement and Registration Statement, will be validly issued, fully paid and non-assessable.

&nbsp;&nbsp;&nbsp;&nbsp;2. The Pre-Funded Warrants and when issued and delivered against payment of the consideration therefore specified in the Underwriting Agreement and Registration Statement, will constitute valid and binding obligations of the Company, enforceable against the Company in accordance with their terms.

&nbsp;&nbsp;&nbsp;&nbsp;3. The Pre-Funded Warrant Shares into which the Pre-Funded Warrants are initially convertible, when issued and delivered upon exercise of the Pre-Funded Warrants in accordance with their terms, will be validly issued, fully paid and non-assessable.

------

Our opinions set forth above are subject to the following qualifications and exceptions:

&nbsp;&nbsp;&nbsp;&nbsp;(a) Our opinion set forth in paragraph 2 above is subject to the effect of any applicable bankruptcy, insolvency, reorganization, moratorium or similar law relating to or affecting creditors' rights generally (including, without limitation, fraudulent conveyance laws).

&nbsp;&nbsp;&nbsp;&nbsp;(b) Our opinion set forth in paragraph 2 above is subject to the effect of general principles of equity, including, without limitation, concepts of materiality, reasonableness, good faith and fair dealing and the possible unavailability of specific performance or injunctive relief, regardless of whether considered in a proceeding in equity or at law.

&nbsp;&nbsp;&nbsp;&nbsp;(c) Our opinion set forth in paragraph 2 above is subject to limitations regarding the availability of indemnification and contribution where such indemnification or contribution may be limited by applicable law or the application of principles of public policy.

&nbsp;&nbsp;&nbsp;&nbsp;(d) We express no opinion as to the enforceability of (i) provisions that relate to choice of law, forum selection or submission to jurisdiction (including, without limitation, any express or implied waiver of any objection to venue in any court or of any objection that a court is an inconvenient forum) to the extent that the validity, binding effect or enforceability of any such provision is to be determined by any court other than a state court of the State of New York, (ii) waivers by the Company of any statutory or constitutional rights or remedies, (iii) terms which excuse any person or entity from liability for, or require the Company to indemnify such person or entity against, such person's or entity's negligence or willful misconduct or (iv) obligations to pay any prepayment premium, default interest rate, early termination fee or other form of liquidated damages, if the payment of such premium, interest rate, fee or damages may be construed as unreasonable in relation to actual damages or disproportionate to actual damages suffered as a result of such prepayment, default or termination.

&nbsp;&nbsp;&nbsp;&nbsp;(e) We draw your attention to the fact that, under certain circumstances, the enforceability of terms to the effect that provisions may not be waived or modified except in writing may be limited.

Our opinions expressed above are limited to the laws of the State of New York.

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement, and to the reference to our firm under the heading "Legal Matters" in the prospectus constituting part of the Registration Statement. In giving this consent, we do not admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission thereunder.

This opinion is intended solely for use in connection with the sale of the Securities subject to the Rule 462(b) Registration Statement and is not to be relied upon for any other purpose.

We assume no obligation to update or supplement any of the opinions set forth herein to reflect any changes of law or fact that may occur after the date hereof.

---

| |
|:---|
| Very truly yours, |
| /s/ Dorsey & Whitney LLP |

---

AE/JE/MP

## Exhibit 23.1

**Exhibit 23.1**

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We have issued our report dated September 26, 2024 (except for Note 20, as to which the date is April 28, 2025) with respect to the consolidated financial statements of Aytu BioPharma, Inc. contained in the Registration Statement on Form S-1, as amended (File No. 333-287728), which is incorporated by reference in this Registration Statement on Form S-1MEF. We consent to the incorporation by reference of the aforementioned report in this Registration Statement, and to the use of our name as it appears under the caption "Experts" in the prospectus incorporated by reference in this Registration Statement.

/s/ GRANT THORNTON LLP

Denver, CO

June 5, 2025

## Ex-Filing

**Exhibit 107** 

**Calculation of Filing Fee Table**

**FORM S-1**

(Form Type)

**AYTU BIOPHARMA, INC.**

(Exact Name of Registrant as Specified in its Charter)

<u>Table 1: Newly Registered Securities</u>

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Security**<br> **Type** | **Security**<br> **Class**<br> **Title** | **Fee**<br> **Calculation** | **Amount**<br> **Registered** | **Proposed**<br> **Maximum**<br> **Offering**<br> **Price Per**<br> **Unit** | **Maximum**<br> **Aggregate**<br> **Offering**<br> **Price<sup>(1)</sup>** | **Fee**<br> **Rate** | **Amount of**<br> **Registration**<br> **Fee<sup>(2)</sup>** |
| Fees to Be Paid | Equity | Common Stock, par value $0.0001 per share | 457(o) |  |  | $2760000 | 0.00015310 | $422.56 |
|  | Other | Prefunded Warrants to purchase shares of Common Stock <sup>(3)</sup> | Other |  |  | - |  |  |
|  | Equity | Common Stock underlying the Prefunded Warrants<sup>(3)</sup> | 457(o) |  |  | - |  |  |
|  | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** |  | $2760000 | 0.00015310 | $422.56 |
|  | **Total Fees Previously Paid** | **Total Fees Previously Paid** | **Total Fees Previously Paid** | **Total Fees Previously Paid** |  |  |  | - |
|  | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** |  |  |  | - |
|  | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** |  |  |  | $422.56 |

---

(1) Represents only the additional shares of the Registrant's common stock, par value $0.0001 per share ("Common Stock") being registered. Does not include the securities that the Registrant previously registered on the Registration Statement on Form S-1, as amended, (File No. 333-287728) (the "Prior Registration Statement"), which was declared effective by the United States Securities and Exchange Commission on June 5, 2025.

(2) The Registrant previously registered an aggregate of $13,800,000 of its Common Stock on the Prior Registration Statement, for which the Registrant previously paid a filing fee of $2,112.78. In accordance with Rule 462(b) under the Securities Act of 1933, as amended, an additional amount of securities having the proposed maximum aggregate offering price of $2,760,000 is hereby registered, which includes shares issuable upon the exercise of the underwriters' option to purchase additional shares.

(3) The proposed maximum aggregate offering price of the shares of Common Stock will be reduced on a dollar-for-dollar basis based on the offering price of any prefunded warrants issued in the offering, and the proposed maximum aggregate offering price of the prefunded warrants to be issued in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any shares of Common Stock issued in the offering.